218 related articles for article (PubMed ID: 17395602)
1. Immunophenotype as prognostic factor for diffuse large B-cell lymphoma in patients undergoing clinical risk-adapted therapy.
Veelken H; Vik Dannheim S; Schulte Moenting J; Martens UM; Finke J; Schmitt-Graeff A
Ann Oncol; 2007 May; 18(5):931-9. PubMed ID: 17395602
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma.
van Imhoff GW; Boerma EJ; van der Holt B; Schuuring E; Verdonck LF; Kluin-Nelemans HC; Kluin PM
J Clin Oncol; 2006 Sep; 24(25):4135-42. PubMed ID: 16943530
[TBL] [Abstract][Full Text] [Related]
3. The importance of Myd88 L265P mutation, clinical and immunohistochemical prognostic factors for the survival of patients with diffuse large B-cell non-Hodgkin lymphoma treated by immunochemotherapy in southeast Serbia.
Tadic L; Marjanovic G; Macukanovic-Golubovic L; Krstic M; Jevtovic-Stoimenov T; Kostov M; Smelcerovic Z; Stojanovic M
J BUON; 2016; 21(5):1259-1267. PubMed ID: 27837631
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of CD44 expression in diffuse large B cell lymphoma of activated and germinal centre B cell-like types: a tissue microarray analysis of 90 cases.
Tzankov A; Pehrs AC; Zimpfer A; Ascani S; Lugli A; Pileri S; Dirnhofer S
J Clin Pathol; 2003 Oct; 56(10):747-52. PubMed ID: 14514777
[TBL] [Abstract][Full Text] [Related]
5. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes.
Jovanovic MP; Mihaljevic B; Jakovic L; Martinovic VC; Fekete MD; Andjelic B; Antic D; Bogdanovic A; Boricic N; Terzic T; Jelicic J; Milenkovic S
J BUON; 2015; 20(3):820-8. PubMed ID: 26214636
[TBL] [Abstract][Full Text] [Related]
6. Nodal diffuse large B-cell lymphomas in children and adolescents: immunohistochemical expression patterns and c-MYC translocation in relation to clinical outcome.
Gualco G; Weiss LM; Harrington WJ; Bacchi CE
Am J Surg Pathol; 2009 Dec; 33(12):1815-22. PubMed ID: 19816150
[TBL] [Abstract][Full Text] [Related]
7. Immunophenotyping of diffuse large B-cell lymphoma (DLBCL) defines multiple sub-groups of germinal centre-like tumours displaying different survival characteristics.
Anderson JJ; Fordham S; Overman L; Dignum H; Wood K; Proctor SJ; Crosier S; Angus B; Culpin RE; Mainou-Fowler T
Int J Oncol; 2009 Nov; 35(5):961-71. PubMed ID: 19787248
[TBL] [Abstract][Full Text] [Related]
8. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma.
Colomo L; López-Guillermo A; Perales M; Rives S; Martínez A; Bosch F; Colomer D; Falini B; Montserrat E; Campo E
Blood; 2003 Jan; 101(1):78-84. PubMed ID: 12393466
[TBL] [Abstract][Full Text] [Related]
9. Serum levels of inflammatory cytokines at diagnosis correlate to the bcl-6 and CD10 defined germinal centre (GC) phenotype and bcl-2 expression in patients with diffuse large B-cell lymphoma.
Pedersen LM; Jürgensen GW; Johnsen HE
Br J Haematol; 2005 Mar; 128(6):813-9. PubMed ID: 15755285
[TBL] [Abstract][Full Text] [Related]
10. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma.
Barrans SL; Carter I; Owen RG; Davies FE; Patmore RD; Haynes AP; Morgan GJ; Jack AS
Blood; 2002 Feb; 99(4):1136-43. PubMed ID: 11830458
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of immunohistochemistry-based markers and algorithms in immunochemotherapy-treated diffuse large B cell lymphoma patients.
Culpin RE; Sieniawski M; Angus B; Menon GK; Proctor SJ; Milne P; McCabe K; Mainou-Fowler T
Histopathology; 2013 Dec; 63(6):788-801. PubMed ID: 24117687
[TBL] [Abstract][Full Text] [Related]
12. Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma.
Lossos IS; Jones CD; Warnke R; Natkunam Y; Kaizer H; Zehnder JL; Tibshirani R; Levy R
Blood; 2001 Aug; 98(4):945-51. PubMed ID: 11493437
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications--a study from the Lunenburg Lymphoma Biomarker Consortium.
de Jong D; Rosenwald A; Chhanabhai M; Gaulard P; Klapper W; Lee A; Sander B; Thorns C; Campo E; Molina T; Norton A; Hagenbeek A; Horning S; Lister A; Raemaekers J; Gascoyne RD; Salles G; Weller E;
J Clin Oncol; 2007 Mar; 25(7):805-12. PubMed ID: 17327602
[TBL] [Abstract][Full Text] [Related]
14. Bcl-6 protein expression, and not the germinal centre immunophenotype, predicts favourable prognosis in a series of primary nodal diffuse large B-cell lymphomas: a single centre experience.
Uccella S; Placidi C; Marchet S; Cergnul M; Proserpio I; Chini C; Novario R; Pinotti G; Capella C
Leuk Lymphoma; 2008 Jul; 49(7):1321-8. PubMed ID: 18604721
[TBL] [Abstract][Full Text] [Related]
15. [Subgrouping and outcome prediction of diffuse large B-cell lymphoma by immunohistochemistry].
Ye ZY; Cao YB; Lin TY; Lin HL
Zhonghua Bing Li Xue Za Zhi; 2007 Oct; 36(10):654-9. PubMed ID: 18194597
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis.
Berglund M; Thunberg U; Amini RM; Book M; Roos G; Erlanson M; Linderoth J; Dictor M; Jerkeman M; Cavallin-Ståhl E; Sundström C; Rehn-Eriksson S; Backlin C; Hagberg H; Rosenquist R; Enblad G
Mod Pathol; 2005 Aug; 18(8):1113-20. PubMed ID: 15920553
[TBL] [Abstract][Full Text] [Related]
17. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
[TBL] [Abstract][Full Text] [Related]
18. Coexpression of MYC and BCL-2 predicts prognosis in primary gastrointestinal diffuse large B-cell lymphoma.
Xia B; Zhang L; Guo SQ; Li XW; Qu FL; Zhao HF; Zhang LY; Sun BC; You J; Zhang YZ
World J Gastroenterol; 2015 Feb; 21(8):2433-42. PubMed ID: 25741152
[TBL] [Abstract][Full Text] [Related]
19. Clinical Significance of
Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
[No Abstract] [Full Text] [Related]
20. Identification of prognostic factors in patients with diffuse large B-cell lymphoma.
Peng F; Guo L; Yao WK; Zheng Y; Liu Y; Duan XM; Wang YP
Indian J Pathol Microbiol; 2017; 60(1):87-91. PubMed ID: 28195099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
